Nasal peptide vaccination elicits CD8 responses and reduces viral burden after challenge with virulent murine cytomegalovirus

Microbiology and Immunology

Volumn 49, Issue 2, 2005, Pages 113-119

  Gopal, Indulekha N ^a,b   Quinn, Anita ^a,b   Henry, Stanley C ^b   Hamilton, John D ^a,b   Staats, Herman F ^a   Frothingham, Richard ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

Author keywords

Cytomegalovirus; Epitope; Nasal peptide vaccination

Indexed keywords

CD8 ANTIGEN; CHOLERA TOXIN; GAMMA INTERFERON; TYROSYLPROLYLHISTIDYLPHENYLALANYLMETHIONYLPROLYLTHREONYLASPARAGINYLLEUCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CELL COUNT; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; FEMALE; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; NONHUMAN; PLAQUE FORMING CELL; PROVOCATION TEST; SALIVARY GLAND; SPLEEN CELL; VACCINATION; VIRUS LOAD; VIRUS VIRULENCE;

ANIMALIA; CYTOMEGALOVIRUS; MAIZE CHLOROTIC MOTTLE VIRUS; MOUSE CYTOMEGALOVIRUS 1; MURINAE;

EID: 14944349507     PISSN: 03855600     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1348-0421.2005.tb03710.x     Document Type: Article

References (39)

1. Carvalho, L.H., Hafalla, J.C., and Zavala, F. 2001. ELISPOT assay to measure antigen-specific murine CD8 (+) T cell responses. J. Immunol. Methods 252: 207-218.
2. Couch, R.B. 2004. Nasal vaccination, Escherichia coli enterotoxin, and Bell's palsy. N. Engl. J. Med. 350: 860-861.
3. Del Val, M., Hengel, H., Hacker, H., Hartlaub, U., Ruppert, T., Lucin, P., and Koszinowski, U.H. 1992. Cytomegalovirus prevents antigen presentation by blocking the transport of peptide-loaded major histocompatibility complex class I molecules into the medial-Golgi compartment. J. Exp. Med. 176: 729-738.
4. Del Val, M., Schlicht, H.J., Volkmer, H., Messerle, M., Reddehase, M.J., and Koszinowski, U.H. 1991. Protection against lethal cytomegalovirus infection by a recombinant vaccine containing a single nonameric T-cell epitope. J. Virol. 65: 3641-3646.
5. Diamond, D.J., York, J., Sun, J.Y., Wright, C.L., and Forman, S.J. 1997. Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood 90: 1751-1767.
6. Douce, G., Fontana, M., Pizza, M., Rappuoli, R., and Dougan, G. 1997. Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin. Infect. Immun. 65: 2821-2828.
7. Elson, C.O., and Balding, W. 1984. Generalized systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin. J. Immunol. 132: 2736-2741.
8. Fernandez, J.A., Zavala, F., and Tsuji, M. 1999. Phenotypic and functional characterization of CD8(+) T cell clones specific for a mouse cytomegalovirus epitope. Virology 255: 40-49.
9. Fujihashi, K., Koga, T., van Ginkel, F.W., Hagiwara, Y., and McGhee, J.R. 2002. A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine 20: 2431-2438.
10. Geginat, G., Ruppert, T., Hengel, H., Holtappels, R., and Koszinowski, U.H. 1997. IFN-gamma is a prerequisite for optimal antigen processing of viral peptides in vivo. J. Immunol. 158: 3303-3310.
11. Gonzalez Armas, J.C., Morello, C.S., Cranmer, L.D., and Spector, D.H. 1996. DNA immunization confers protection against murine cytomegalovirus infection. J. Virol. 70: 7921-7928.
12. Hengel, H., Lucin, P., Jonjic, S., Ruppert, T., and Koszinowski, U.H. 1994. Restoration of cytomegalovirus antigen presentation by gamma interferon combats viral escape. J. Virol. 68: 289-297.
13. Henry, S.C., Schmader, K., Brown, T.T., Miller, S.E., Howell, D.N., Daley, G.G., and Hamilton, J.D. 2000. Enhanced green fluorescent protein as a marker for localizing murine cytomegalovirus in acute and latent infection. J. Virol. Methods 89: 61-73.
14. Kashiwagi, Y., Nemoto, S., Kawashima, H., Takekuma, K., Matsuno, T., Hoshika, A., and Nozaki-Renard, J. 2001. Cytomegalovirus DNA among children attending two daycare centers in Tokyo. Pediatr. Int. 43: 493-495.
15. La Rosa, C., Wang, Z., Brewer, J.C., Lacey, S.F., Villacres, M.C., Sharan, R., Krishnan, R., Crooks, M., Markel, S., Maas, R., and Diamond, D.J. 2002. Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice. Blood 100: 3681-3689.
16. Lucin, P., Pavic, I., Polic, B., Jonjic, S., and Koszinowski, U.H. 1992. Gamma interferon-dependent clearance of cytomegalovirus infection in salivary glands. J. Virol. 66: 1977-1984.
17. Lutarewych, M.A., Quirk, M.R., Kringstad, B.A., Li, W., Verfaillie, C.M., and Jordan, M.C. 1997. Propagation and titration of murine cytomegalovirus in a continuous bone marrow-derived stromal cell line (M2-10B4). J. Virol. Methods 68: 193-198.
18. MacDonald, M.R., Li, X.Y., Stenberg, R.M., Campbell, A.E., and Virgin, H.W. 1998. Mucosal and parenteral vaccination against acute and latent murine cytomegalovirus (MCMV) infection by using an attenuated MCMV mutant. J. Virol. 72: 442-451.
19. Morley, P.J., Ertl, P.F., and Sweet, C. 2003. High-frequency interferon-gamma-secreting splenocytes specific for murine cytomegalovirus immediate-early-1 (IE-1) peptide 168YPHFMPTNL176 are insufficient to provide complete protection from viral challenge. J. Med. Virol. 69: 240-250.
20. Mutsch, M., Zhou, W., Rhodes, P., Bopp, M., Chen, R.T., Linder, T., Spyr, C., and Steffenm, R. 2004. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N. Engl. J. Med. 350: 896-903.
21. Nishimura, N., Kimura, H., Yabuta, Y., Tanaka, N., Ito, Y., Ishikawa, K., Suzuki, C., and Morishima, T. 1999. Prevalence of maternal cytomegalovirus (CMV) antibody and detection of CMV DNA in amniotic fluid. Microbiol. Immunol. 43: 781-784.
22. Ohtomo, K., Wang, S., Masunaga, A., Iwamoto, A., and Sugawara, I. 2000. Secondary infections of AIDS autopsy cases in Japan with special emphasis on Mycobacterium avium-intracellulare complex infection. Tohoku J. Exp. Med. 192: 99-109.
23. Podlech, J., Holtappels, R., Wirtz, N., Steffens, H.P., and Reddehase, M.J. 1998. Reconstitution of CD8 T cells is essential for the prevention of multiple-organ cytomegalovirus histopathology after bone marrow transplantation. J. Gen. Virol. 79 (Pt 9): 2099-2104.
24. Porgador, A., and Gilboa, E. 1995. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J. Exp. Med. 182: 255-260.
25. Porgador, A., Staats, H.F., Faiola, B., Gilboa, E., and Palker, T.J. 1997. Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo. J. Immunol. 158: 834-841.
26. Reddehase, M.J. 2000. The immunogenicity of human and murine cytomegaloviruses. Curr. Opin. Immunol. 12: 390-396.
27. Reddehase, M.J., Mutter, W., Munch, K., Buhring, H.J., and Koszinowski, U.H. 1987. CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity. J. Virol. 61: 3102-3108.
28. Reddehase, M.J., Rothbard, J.B., and Koszinowski, U.H. 1989. A pentapeptide as minimal antigenic determinant for MHC class I-restricted T lymphocytes. Nature 337: 651-653.
29. Sasaki, S., Hamajima, K., Fukushima, J., Ihata, A., Ishii, N., Gorai, I., Hirahara, F., Mohri, H., and Okuda, K. 1998. Comparison of intranasal and intramuscular immunization against human immunodeficiency virus type 1 with a DNA-monophosphoryl lipid A adjuvant vaccine. Infect. Immun. 66: 823-826.
30. Scalzo, A.A., Elliott, S.L., Cox, J., Gardner, J., Moss, D.J., and Suhrbier, A. 1995. Induction of protective cytotoxic T cells to murine cytomegalovirus by using a nonapeptide and a human-compatible adjuvant (Montanide ISA 720). J. Virol. 69: 1306-1309.
31. Schleiss, M.R., Bourne, N., and Bernstein, D.I. 2003. Preconception vaccination with a glycoprotein B (gB) DNA vaccine protects against cytomegalovirus (CMV) transmission in the guinea pig model of congenital CMV infection. J. Infect. Dis. 188: 1868-1874.
32. Schmader, K., Henry, S.C., Rahija, R.J., Yu, Y., Daley, G.G., and Hamilton, J.D. 1995. Mouse cytomegalovirus reactivation in severe combined immune deficient mice after implantation of latently infected salivary gland. J. Infect. Dis. 172: 531-534.
33. Sia, I.G., and Patel, R. 2000. New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients. Clin. Microbiol. Rev. 13: 83-121.
34. Staats, H.F., Bradney, C.P., Gwinn, W.M., Jackson, S.S., Sempowski, G.D., Liao, H.X., Letvin, N.L., and Haynes, B.F. 2001. Cytokine requirements for induction of systemic and mucosal CTL after nasal immunization. J. Immunol. 167: 5386-5394.
35. Staats, H.F., Montgomery, S.P., and Palker, T.J. 1997. Intranasal immunization is superior to vaginal, gastric, or rectal immunization for the induction of systemic and mucosal anti-HIV antibody responses. AIDS Res. Hum. Retroviruses 13: 945-952.
36. Staats, H.F., Nichols, W.G., and Palker, T.J. 1996. Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN (A). J. Immunol. 157: 462-472.
37. Steffens, H.P., Kurz, S., Holtappels, R., and Reddehase, M.J. 1998. Preemptive CD8 T-cell immunotherapy of acute cytomegalovirus infection prevents lethal disease, limits the burden of latent viral genomes, and reduces the risk of virus recurrence. J. Virol. 72: 1797-1804.
38. Sweet, C. 1999. The pathogenicity of cytomegalovirus. FEMS Microbiol. Rev. 23: 457-482.
39. Yu, Y., Henry, S.C., Xu, F., and Hamilton, J.D. 1995. Expression of a murine cytomegalovirus early-late protein in "latently" infected mice. J. Infect. Dis. 172: 371-379.